{"id":26904,"date":"2021-03-25T14:30:00","date_gmt":"2021-03-25T14:30:00","guid":{"rendered":"http:\/\/23d44bc2a048858c6367a0ffc428c384"},"modified":"2024-11-03T15:15:00","modified_gmt":"2024-11-03T15:15:00","slug":"longer-follow-up-continues-to-support-first-line-pembrolizumab-plus-chemotherapy-in-metastatic-squamous-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/longer-follow-up-continues-to-support-first-line-pembrolizumab-plus-chemotherapy-in-metastatic-squamous-non-small-cell-lung-cancer\/","title":{"rendered":"Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer"},"content":{"rendered":"

Updated results from the phase III KEYNOTE-407 study reported at the European Lung Cancer Virtual Congress 2021<\/a> (25-27 March) demonstrated that survival and response rates remained improved with pembrolizumab plus chemotherapy over placebo plus chemotherapy in treatment-naive patients with metastatic squamous non-small cell lung cancer (NSCLC).<\/p>\n

Andrew G. Robinson of the Cancer Centre of Southeastern Ontario at Kingston General Hospital in Kingston, Canada presented long-term findings from the KEYNOTE-407 study (NCT02775435) including in patients who received up to 35 cycles or approximately 2 years of pembrolizumab.<\/p>\n

A prior report from the protocol-specified final analysis in May 2019 showed that patients with previously untreated metastatic squamous NSCLC receiving pembrolizumab plus carboplatin together with paclitaxel or nab-paclitaxel had significantly improved overall survival (OS) compared to those receiving only chemotherapy (hazard ratio [HR] 0.71; 95% confidence interval [CI] 0.58\u20130.88).<\/p>\n

The randomised, double-blind, phase III KEYNOTE-407 study compared pembrolizumab at 200 mg plus chemotherapy in 278 patients versus placebo plus chemotherapy in 281 patients every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles. Chemotherapy consisted of carboplatin plus a taxane (paclitaxel or nab-paclitaxel). The patients were stratified according to paclitaxel versus nab-paclitaxel, East Asia versus rest of the world, and PD-L1 tumour proportion score (TPS) \u22651% versus <1%.<\/p>\n

The primary endpoints of this study were OS and progression-free survival (PFS) per RECIST v1.1 by blinded independent central review.<\/p>\n

Patients completing 35 pembrolizumab cycles showed the most improved outcomes<\/h4>\n

On 30 September 2020, the median time from randomisation to data cutoff was 40.1 (range, 33.1 to 49.4) months. By this time, 143 (51.1%) patients had crossed over from the placebo\/chemotherapy arm to receive either pembrolizumab monotherapy on study or received another anti\u2212PD-(L)1 therapy.<\/p>\n

OS was improved with the addition of pembrolizumab to chemotherapy; median OS with pembrolizumab\/chemotherapy was 17.2 compared to 11.6 months with placebo\/chemotherapy (HR 0.71; 95% CI 0.59\u22120.86). Three-year OS rates of 29.7% versus 18.2% were observed with pembrolizumab\/chemotherapy versus placebo\/chemotherapy, respectively.<\/p>\n

\n
\n
\"Longer-Follow-Up-Continues-to-Support-First-Line-Pembrolizumab-Plus-Chemotherapy-in-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer\"
\n
\n

Pembrolizumab plus chemotherapy continued to provide a benefit in overall survival over placebo plus chemotherapy with over 3 years of follow-up.<\/p>\n

\u00a9 Andrew G. Robinson.<\/p>\n<\/div>\n<\/figcaption><\/figure>\n<\/div>\n<\/div>\n

The median PFS was also improved with the addition of pembrolizumab to chemotherapy, 8.0 versus<\/em> 5.1 months (HR 0.59; 95% CI 0.49\u22120.71); the 3-year PFS rates were 16.1% with pembrolizumab versus 6.5% with placebo. In the respective treatment groups, median PFS2 was 13.8 versus 9.1 months (HR 0.59; 95% CI 0.49\u22120.71).<\/p>\n

Adding pembrolizumab to chemotherapy improved the objective response rate (ORR) to 62.6% compared to 38.8% with placebo\/chemotherapy and the median duration of response was 9.0 (range, 1.3+ to 45.0+) months compared to 4.9 (range, 1.3+ to 44.8+) months, respectively.<\/p>\n

Among the 55 patients completing 35 cycles of pembrolizumab, the ORR was 92.7%, which included 5 patients with complete response and 46 with partial response; 4 (7.3%) patients had stable disease. After completion of 35 pembrolizumab cycles, 51 (92.7%) patients were alive. The 1-year OS and PFS rates from completion of pembrolizumab were 96.0% and 82.6%, respectively. As of data cut-off, 7 patients had initiated a second course of pembrolizumab.<\/p>\n

The incidence of Grade 3\u22125 adverse events was similar in both arms, at 74.8% with pembrolizumab\/chemotherapy and 70.0% with placebo\/chemotherapy.<\/p>\n

Conclusions<\/h4>\n

Based upon these findings, the authors concluded that pembrolizumab plus chemotherapy continued to demonstrate durable benefit with >3 years of follow-up as compared to placebo plus chemotherapy, without additional toxicity.<\/p>\n

They noted that the majority of patients completing 35 cycles showed objective responses and were alive at data cut-off.<\/p>\n

According to the authors, these long-term data continue to support pembrolizumab plus chemotherapy as first-line treatment in patients with metastatic squamous NSCLC.<\/p>\n

This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.<\/p>\n

Reference<\/h4>\n

97O – Robinson AG, Vicente D, Tafreshi A, et al.<\/em> First-Line Pembrolizumab Plus Chemotherapy for Patients With Advanced Squamous NSCLC: 3-Year Follow-up From KEYNOTE-407. European Lung Cancer Virtual Congress 2021<\/a> (25-27 March).<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Updated results from the phase III KEYNOTE-407 study reported at the European Lung Cancer Virtual Congress 2021 (25-27 March) demonstrated that survival and response rates remained improved with pembrolizumab plus chemotherapy over placebo plus chemotherapy in treatment-naive patients with metastatic squamous non-small cell lung cancer (NSCLC). Andrew G. Robinson of the Cancer Centre of Southeastern Ontario […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-26904","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=26904"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26904\/revisions"}],"predecessor-version":[{"id":43889,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/26904\/revisions\/43889"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=26904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=26904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=26904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}